An Israeli research team has concluded that THC inhalers can be used to successfully manage chronic pain symptoms with minimal side effects.
A new study conducted by a team of Israeli scientists—that was published in the European Journal of Pain in May 2020—has found that precisely controlled doses of THC can be an effective method of minimizing pain symptoms in neuropathy patients.
The randomized placebo-controlled study administered the drug via THC inhalers to a test group of 27 chronic pain patients, who were then subdivided into three test groups.
Both doses, but not the placebo, demonstrated a significant reduction in pain intensity compared with baseline and remained stable for 150 minutes. The 1 mg dose showed a significant pain decrease compared to the placebo. Adverse events were mostly mild and resolved spontaneously. There was no evidence of consistent impairments in cognitive performance. The Pharmacokinetics, Efficacy, and Safety of a Novel Selective‐Dose Cannabis Inhaler in Patients with Chronic Pain
The first and second group of patients were given a 1 mg and 0.5 mg THC dose, respectively, while the third cohort received a placebo.
The researchers also believe that the study's findings could also be used in future to assist with determining individualized dosage levels for medicinal marijuana prescriptions.
The data taken from this trial will be used to build on previous research that has also examined the use of cannabis inhalers in a medical setting. Previous studies have also confirmed novel THC inhaler devices can be used to successfully manage pain symptoms while also displaying a minimal side effect profile.
"This feasibility trial demonstrated that a metered-dose cannabis inhaler delivered precise and low THC doses [that] produced a dose-dependent and safe analgesic effect in patients with neuropathic pain/complex-regional pain syndrome (CRPS)," the report stated.
"Thus, it enables individualization of medical cannabis regimens that can be evaluated pharmacokinetically and pharmacodynamically by accepted pharmaceutical models."
The study's publication follows the recent announcement of a similar project by Cannabis Radar, which analysed randomized data from 700 participants to determine if CBD can be used to reduce cigarette consumption.
"The participants were asked to inhale CBD oil with the help of an inhaler every time they felt the urge to smoke. We then broke down the entire sample into three groups as per their ages," Cannabis Radar stated.
"As per their ages, we went with three distinct age groups when smoking is usually a habit and people are more or less dependent on it. These age groups are 25 – 35 years, 36 – 45 years, and 46 – 55 years."
The study found that just over 42% of smokers—which represents 297 of the 700 applicants—were able to abstain from smoking for a month through the use of CBD products.
This pot stock could reach new heights in 2020 due to Coronavirus
The COVID-19 pandemic is showing no signs of slowing down, and as global markets enter meltdown many cannabis companies are feeling the effects of capital crunch.
While the market crash will continue for some time, it represents a golden opportunity for investors who are capable of riding out the volatility until share prices rally.
Luckily, one pot stock has developed antimicrobial drug that can already treat two superbugs while limiting their ability to develop antibiotic resistance.
Investors can also start picking up shares at rock bottom prices, as global investor sentiment continues to dampen thanks to COVID-19.
Get the Latest Marijuana News &
Content in your Inbox!
All your support helps The Green Fund keep writing content for all you
marijuana enthusiasts and potential pot stock investors